Integrated Filing — IndAS



General information about company
Scrip Code 000000
NSE Symbol ZENITHDRUG
MSEI Symbol NOTLISTED
ISIN INE0QWN01013
Name of company ZENITH DRUGS LIMITED
Type of company SME
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 29-May-2025   14:00:00
End date and time of board meeting 29-May-2025   19:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public No
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. No
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2023-09-25
Indicate Company website link for updated RPT policy of the Company www.zenithdrugs.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company has not defaulted on any loans or debt securities.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 656252000 1333200000
Other income 17396000 26057000
Total income 673648000 1359257000
2 Expenses
(a) Cost of materials consumed 412124000 880712000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -3929000 -5905000
(d) Employee benefit expense 39802000 73303000
(e) Finance costs 24700000 37108000
(f) Depreciation, depletion and amortisation expense
(f) Other Expenses
1 Other Operating Expenses 55654000 98669000
2 Other expenses 84611000 150636000
Total other expenses 140265000 249305000
Total expenses 635763000 1264186000
3 Total profit before exceptional items and tax
4 Exceptional items
5 Total profit before tax 35421000 92607000
6 Tax expense
7 Current tax 20461000 20461000
8 Deferred tax 540000 540000
9 Total tax expenses 21001000 21001000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement
11 Net Profit Loss for the period from continuing operations
12 Profit (loss) from discontinued operations before tax
13 Tax expense of discontinued operations
14 Net profit (loss) from discontinued operation after tax
15 Share of profit (loss) of associates and joint ventures accounted for using equity method
16 Total profit (loss) for period
17 Other comprehensive income net of taxes
18 Total Comprehensive Income for the period
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1714880000000 1714880000000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 522304000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations
Diluted earnings (loss) per share from continuing operations
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations
Diluted earnings (loss) per share from discontinued operations
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.84 4.18
Diluted earnings (loss) per share from continuing and discontinued operations 0.84 4.18
24 Debt equity ratio 0.0133 0.0133
25 Debt service coverage ratio 0.0076 0.0306
26 Interest service coverage ratio 0.042 0.052
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 400839000
Capital work-in-progress
Investment property
Goodwill
Other intangible assets
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 0
Trade receivables, non-current
Loans, non-current
Other non-current financial assets
Total non-current financial assets
Deferred tax assets (net) 116000
Other non-current assets 29272000
Total non-current assets 463004000
2 Current assets
Inventories 396123000
Current financial asset
Current investments 0
Trade receivables, current
Cash and cash equivalents 2630000
Bank balance other than cash and cash equivalents 0
Loans, current
Other current financial assets
Total current financial assets
Current tax assets (net)
Other current assets 26991000
Total current assets 1151768000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1614772000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital
Other equity
Total equity attributable to owners of parent
Non controlling interest
Total equity
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
Total non-current financial liabilities
Provisions, non-current
Deferred tax liabilities (net) 0
Deferred government grants, Non-current
Other non-current liabilities
Total non-current liabilities 127955000
Current liabilities
Current financial liabilities
Borrowings, current
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other current financial liabilities
Total current financial liabilities
Other current liabilities 9738000
Provisions, current
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 793025000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities
Total equity and liabilites 1614772000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Oct-2024 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 92607000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 37108000
Adjustments for decrease (increase) in inventories -138540000
Adjustments for decrease (increase) in trade receivables, current
Adjustments for decrease (increase) in trade receivables, non-current
Adjustments for decrease (increase) in other current assets 0
Adjustments for decrease (increase) in other non-current assets
Adjustments for other financial assets, non-current
Adjustments for other financial assets, current
Adjustments for other bank balances
Adjustments for increase (decrease) in trade payables, current
Adjustments for increase (decrease) in trade payables, non-current
Adjustments for increase (decrease) in other current liabilities -40738000
Adjustments for increase (decrease) in other non-current liabilities
Adjustments for depreciation and amortisation expense 29663000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current
Adjustments for provisions, non-current
Adjustments for other financial liabilities, current
Adjustments for other financial liabilities, non-current
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income
Adjustments for share-based payments 0
Adjustments for fair value losses (gains)
Adjustments for undistributed profits of associates
Other adjustments for which cash effects are investing or financing cash flow -2923000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -92159000
Net cash flows from (used in) operations 2912000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 20461000
Other inflows (outflows) of cash -37108000
Net cash flows from (used in) operating activities -54657000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 714000
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 321129000
Proceeds from sales of investment property
Purchase of investment property
Proceeds from sales of intangible assets 0
Purchase of intangible assets 1705000
Proceeds from sales of intangible assets under development
Purchase of intangible assets under development
Proceeds from sales of goodwill
Purchase of goodwill
Proceeds from biological assets other than bearer plants
Purchase of biological assets other than bearer plants
Proceeds from government grants 0
Proceeds from sales of other long-term assets
Purchase of other long-term assets
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 8051000
Net cash flows from (used in) investing activities -314069000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries
Payments from changes in ownership interests in subsidiaries
Proceeds from issuing shares
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares
Payments of other equity instruments
Proceeds from exercise of stock options
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 246349000
Repayments of borrowings -37578000
Payments of lease liabilities
Dividends paid 0
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities 283927000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -84799000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -84799000
Cash and cash equivalents cash flow statement at beginning of period 87429000
Cash and cash equivalents cash flow statement at end of period 2630000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 V D S & Company Yes 30-Jun-2026


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 ZENITH DRUGS LIMITED Biogenesis Corp Firm in which director, manager or his relative is a partner Purchase of goods or services 10000000000000 NA 7375623800000 0 0
2 ZENITH DRUGS LIMITED Biogenesis Corp Firm in which director, manager or his relative is a partner Sale of goods or services 13000000000000 NA 12941852900000 0 0
3 ZENITH DRUGS LIMITED Priyanka Bhardwaj Wife of Director Any other transaction Salary 90000000000 NA 18000000000 0 0
4 ZENITH DRUGS LIMITED Anjali Dassundi Wife of Director Any other transaction Salary 90000000000 NA 18000000000 0 0
5 ZENITH DRUGS LIMITED Jaywanti Soni Wife of Director Any other transaction Salary 90000000000 NA 18000000000 0 0
6 ZENITH DRUGS LIMITED Sandeep Bhardwaj Director Any other transaction Sale of Investment 23800000000 NA 23800000000 0 0
7 ZENITH DRUGS LIMITED Bhupesh Soni Director Any other transaction Sale of Investment 23800000000 NA 23800000000 0 0
8 ZENITH DRUGS LIMITED Ajay Singh Dassundi Director Any other transaction Sale of Investment 23800000000 NA 23800000000 0 0
9 ZENITH DRUGS LIMITED Veena Bharbhaya Sister of Director Any other transaction Consultancy Services 50000000000 NA 30000000000 0 0
10 ZENITH DRUGS LIMITED AM HR Solutions Firm in which director, manager or his relative is a partner Any other transaction Consultancy Services 100000000000 NA 46376600000 0 0
11 ZENITH DRUGS LIMITED Priyanka Bhardwaj Wife of Director Dividend paid 16650000000 NA 16650000000 0 0
12 ZENITH DRUGS LIMITED Anjali Dassundi Wife of Director Dividend paid 6900000000 NA 6900000000 0 0
13 ZENITH DRUGS LIMITED Jaywanti Soni Wife of Director Dividend paid 25200000000 NA 25200000000 0 0
14 ZENITH DRUGS LIMITED Sandeep Bhardwaj Director Dividend paid 183349500000 NA 183349500000 0 0
15 ZENITH DRUGS LIMITED Bhupesh Soni Director Dividend paid 173049000000 NA 173049000000 0 0
16 ZENITH DRUGS LIMITED Ajay Singh Dassundi Director Dividend paid 193099500000 NA 193099500000 0 0
17 ZENITH DRUGS LIMITED Saroj Soni Mother of Director Dividend paid 1752000000 NA 1752000000 0 0
18 ZENITH DRUGS LIMITED Kavya Bhardwaj Son of Director Any other transaction Internship stipend 30000000000 NA 5000000000 0 0
19 ZENITH DRUGS LIMITED Sandeep Bhardwaj Director Remuneration 750000000000 NA 304000000000 0 0
20 ZENITH DRUGS LIMITED Bhupesh Soni Director Remuneration 750000000000 NA 366800000000 0 0
21 ZENITH DRUGS LIMITED Ajay Singh Dassundi Director Remuneration 750000000000 NA 106000000000 0 0
22 ZENITH DRUGS LIMITED Deendayal Kumawat Director Any other transaction Sitting Fees 8500000000 NA 8500000000 0 0
23 ZENITH DRUGS LIMITED Ranjana Sureshkumar Sehgal Director Any other transaction Sitting Fees 8000000000 NA 8000000000 0 0
24 ZENITH DRUGS LIMITED Anil Malik Director Any other transaction Sitting Fees 5500000000 NA 5500000000 0 0
25 ZENITH DRUGS LIMITED Deendayal Kumawat Director Any other transaction Reimbursement of expenses 3423600000 NA 3423600000 0 0
26 ZENITH DRUGS LIMITED Sandeep Bhardwaj Director Interest paid 240100400000 NA 240100400000 2041758000000 1629048400000
27 ZENITH DRUGS LIMITED Bhupesh Soni Director Interest paid 179820000000 NA 179820000000 1549980300000 1088018200000
28 ZENITH DRUGS LIMITED Ajay Singh Dassundi Director Interest paid 90313700000 NA 90313700000 273125000000 1065642700000
Total value of transaction during the reporting period 22436711000000